BioLineRx to Report Second Quarter 2026 Results on August 31, 2026

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) announced it will release unaudited financial results for the second quarter ended June 30, 2026, on Monday, August 31, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT, featuring remarks by CEO Philip Serlin.

Investors can join the call by dialing +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and replay will be available via the event page on the company’s website. A dial-in replay will be accessible until September 1, 2026, at +1-888-295-2634 (U.S.) or +972-3-925-5904 (international).

Market Context

-0.75% was the average 24-hour move across three prior earnings-date announcements, providing a tag-...

Analysis

-0.75% was the average 24-hour move across three prior earnings-date announcements, providing a tag-specific baseline for this scheduling notice. The release adds timing only; the forthcoming financial results remain the key information risk.

Key Figures

Results period: Second quarter 2026 Reporting period end: June 30, 2026 Release date: August 31, 2026 +1 more

4 metrics

Results period Second quarter 2026 Unaudited financial results

Reporting period end June 30, 2026 Second quarter 2026

Release date August 31, 2026 Before U.S. markets open

Conference call time 8:30 a.m. EDT August 31, 2026

Previous Earnings date Reports

3 past events · Latest: May 20 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
May 20	Q1 results date	Neutral	+4.6%	Announced Q1 2026 results release date and management conference call
Mar 16	Annual results date	Neutral	-1.5%	Announced 2025 annual results release date and management conference call
Nov 18	Q3 results date	Neutral	-5.3%	Announced third-quarter 2025 results release date and conference call

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date announcements produced mixed reactions of +4.56%, -1.5%, and -5.31%, averaging -0.75%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2026 on Monday, August 31, 2026, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until September 1, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

CONTACTS:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-second-quarter-2026-results-on-august-31-2026-302859223.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) report its Q2 2026 financial results?

BioLineRx will report its unaudited Q2 2026 financial results on August 31, 2026, before U.S. markets open. According to BioLineRx, the results cover the quarter ended June 30, 2026, and will be followed by a management conference call.

What time is the BioLineRx (BLRX) Q2 2026 earnings conference call on August 31, 2026?

The BioLineRx Q2 2026 conference call is scheduled for 8:30 a.m. EDT on August 31, 2026. According to BioLineRx, the call will include prepared remarks from CEO Philip Serlin and is open to investors via phone and webcast.

How can investors access the BioLineRx (BLRX) Q2 2026 earnings call and webcast?

Investors can dial +1-888-407-2553 (U.S.) or +972-3-918-0685 (international) to join live. According to BioLineRx, a live webcast and replay will also be available through the event page on the company’s website after allowing time to install any required software.

Will there be a replay of the BioLineRx (BLRX) Q2 2026 earnings conference call?

Yes, a replay will be available starting about two hours after the live call. According to BioLineRx, dial-in replay is accessible until September 1, 2026 at +1-888-295-2634 (U.S.) or +972-3-925-5904 (international), with a webcast replay on the website.

Who will speak on the BioLineRx (BLRX) Q2 2026 earnings call on August 31, 2026?

The Q2 2026 earnings call will feature remarks by Philip Serlin, Chief Executive Officer of BioLineRx. According to BioLineRx, Serlin will lead the discussion of unaudited results and business updates during the scheduled 8:30 a.m. EDT call.